Hybio Pharmaceutical Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hybio Pharmaceutical Co Ltd with three other
companies in this sector in China:
Anhui Anke Biotechnology (Group) Company., Limited
sales of 849.19 million Chinese Renmimbi [US$129.15 million]
of which 57%
was Biological Products),
Tianjin Lisheng Pharmaceutical Company Limited
(846.83 million Chinese Renmimbi [US$128.79 million]
of which 100%
was Phamaceutical Manufacturing), and
Zhejiang Yatai Pharmaceutical Co.,Limited
(862.87 million Chinese Renmimbi [US$131.23 million]
of which 53%
was CRO Service).
Hybio Pharmaceutical Co Ltd reported sales of 855.05 million Chinese Renmimbi (US$130.04 million)
December of 2016.
increase of 11.3%
versus 2015, when the company's sales were 768.26 million Chinese Renmimbi.
Sales at Hybio Pharmaceutical Co Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 416%).